These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17211054)

  • 21. Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential.
    Rucker JJ
    BMJ; 2015 May; 350():h2902. PubMed ID: 26014506
    [No Abstract]   [Full Text] [Related]  

  • 22. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects.
    Strassman RJ
    J Nerv Ment Dis; 1995 Mar; 183(3):127-38. PubMed ID: 7891058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classic hallucinogens in the treatment of addictions.
    Bogenschutz MP; Johnson MW
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():250-8. PubMed ID: 25784600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The hallucinogenic drugs--their use and abuse.
    Med J Aust; 1968 Jan; 1(4):146-7. PubMed ID: 5641090
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
    Halpern JH; Sherwood AR; Passie T; Blackwell KC; Ruttenber AJ
    Med Sci Monit; 2008 Aug; 14(8):SR15-22. PubMed ID: 18668010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of alcoholism using psychedelic drugs: a review of the program of research.
    Mangini M
    J Psychoactive Drugs; 1998; 30(4):381-418. PubMed ID: 9924844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.
    Dos Santos RG; Bouso JC; Hallak JEC
    Ther Adv Psychopharmacol; 2017 Apr; 7(4):141-157. PubMed ID: 28540034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans.
    Bouso JC; Palhano-Fontes F; Rodríguez-Fornells A; Ribeiro S; Sanches R; Crippa JA; Hallak JE; de Araujo DB; Riba J
    Eur Neuropsychopharmacol; 2015 Apr; 25(4):483-92. PubMed ID: 25637267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
    Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
    Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hashish and LSD. Physical and psychic effects. 1].
    Remschmidt H
    Med Klin; 1972 May; 67(20):706-16 contd. PubMed ID: 5042087
    [No Abstract]   [Full Text] [Related]  

  • 34. Herbal drugs of abuse: an emerging problem.
    Richardson WH; Slone CM; Michels JE
    Emerg Med Clin North Am; 2007 May; 25(2):435-57; abstract ix. PubMed ID: 17482027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Not imagining it. Research into hallucinogens cautiously resumes.
    Biello D
    Sci Am; 2006 Nov; 295(5):33-5. PubMed ID: 17076078
    [No Abstract]   [Full Text] [Related]  

  • 36. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.
    Krebs TS; Johansen PØ
    J Psychopharmacol; 2012 Jul; 26(7):994-1002. PubMed ID: 22406913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating drug dependence with the aid of ibogaine: a retrospective study.
    Schenberg EE; de Castro Comis MA; Chaves BR; da Silveira DX
    J Psychopharmacol; 2014 Nov; 28(11):993-1000. PubMed ID: 25271214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
    Heekeren K; Neukirch A; Daumann J; Stoll M; Obradovic M; Kovar KA; Geyer MA; Gouzoulis-Mayfrank E
    J Psychopharmacol; 2007 May; 21(3):312-20. PubMed ID: 17591658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects.
    Barbosa PC; Cazorla IM; Giglio JS; Strassman R
    J Psychoactive Drugs; 2009 Sep; 41(3):205-12. PubMed ID: 19999673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire.
    Baggott MJ; Coyle JR; Erowid E; Erowid F; Robertson LC
    Drug Alcohol Depend; 2011 Mar; 114(1):61-7. PubMed ID: 21035275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.